Lingohr Asset Management GmbH Takes Position in Abbott Laboratories (NYSE:ABT)

Lingohr Asset Management GmbH purchased a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 7,935 shares of the healthcare product maker's stock, valued at approximately $890,000. Abbott Laboratories accounts for 1.8% of Lingohr Asset Management GmbH's holdings, making the stock its 16th largest position.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Groupama Asset Managment grew its position in Abbott Laboratories by 22.2% in the 3rd quarter. Groupama Asset Managment now owns 228,448 shares of the healthcare product maker's stock valued at $26,000 after acquiring an additional 41,557 shares in the last quarter. Noble Wealth Management PBC purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $26,000. NewSquare Capital LLC increased its stake in Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after buying an additional 105 shares during the period. Rialto Wealth Management LLC acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $29,000. Finally, Wingate Wealth Advisors Inc. purchased a new position in Abbott Laboratories in the 4th quarter valued at approximately $34,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Performance

NYSE:ABT traded up $0.97 during mid-day trading on Monday, reaching $127.31. 5,283,007 shares of the stock were exchanged, compared to its average volume of 5,481,777. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $141.23. The company has a 50 day simple moving average of $128.79 and a 200-day simple moving average of $120.04. The stock has a market capitalization of $220.79 billion, a P/E ratio of 16.64, a P/E/G ratio of 2.52 and a beta of 0.70.

Remove Ads

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, meeting analysts' consensus estimates of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business had revenue of $10.97 billion for the quarter, compared to analysts' expectations of $11.03 billion. During the same period in the previous year, the company posted $1.19 EPS. The company's quarterly revenue was up 7.2% on a year-over-year basis. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.85%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories's dividend payout ratio is currently 30.85%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Citigroup upped their price objective on Abbott Laboratories from $135.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Argus raised Abbott Laboratories to a "strong-buy" rating in a research report on Tuesday, January 28th. Royal Bank of Canada reissued an "outperform" rating and set a $135.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, January 21st. UBS Group raised their target price on shares of Abbott Laboratories from $146.00 to $148.00 and gave the company a "buy" rating in a report on Thursday, January 23rd. Finally, Evercore ISI increased their price objective on shares of Abbott Laboratories to $136.00 and gave the company a "buy" rating in a research report on Thursday, January 2nd. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $137.94.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Lisa D. Earnhardt sold 91,167 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total value of $12,199,967.94. Following the transaction, the executive vice president now owns 71,928 shares of the company's stock, valued at approximately $9,625,404.96. The trade was a 55.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the sale, the executive vice president now directly owns 125,697 shares of the company's stock, valued at approximately $16,152,064.50. This represents a 15.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 116,449 shares of company stock valued at $15,463,316 in the last ninety days. Insiders own 1.10% of the company's stock.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.